Mumbai, Mar 5 (UNI) Pharma major, Zydus Lifesciences on Wednesday said that it has launched ANVIMO (Letermovir), a new and innovative treatment for the prevention of Cytomegalovirus (CMV) infection in Hematopoietic Stem Cell Transplantation (HSCT) and kidney transplant patients.